FilingPulse

INZY insider filings

Inozyme Pharma, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2025-07-03. Screen INZY transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for INZY between 2026-07-10 and 2026-10-08. The table below lists the most recent filings on record.

Recent insider filings — Inozyme Pharma, Inc.

FiledFormInsiderReported transactionsSource
2025-07-034Subramanian Sanjay — SVP, CFO & Head of BDCode (U): 39,701 @ $4 · Disposition to issuer (D): 38,500 (derivative) · Disposition to issuer (D): 180,000 (derivative) · Disposition to issuer (D): 135,000 (derivative) · Disposition to issuer (D): 145,000 (derivative)EDGAR
2025-07-034Winton Matthew — COOCode (U): 21,743 @ $4 · Disposition to issuer (D): 41,500 (derivative) · Disposition to issuer (D): 145,000 (derivative)EDGAR
2025-07-034Sullivan Lynne Marie — DirectorDisposition to issuer (D): 28,368 (derivative)EDGAR
2025-07-034Treco Douglas A — CEO & Chairman, DirectorCode (U): 43,861 @ $4 · Disposition to issuer (D): 150,000 (derivative) · Disposition to issuer (D): 86,979 (derivative) · Disposition to issuer (D): 400,000 (derivative)EDGAR
2025-07-034Bolte Axel — DirectorCode (U): 423,926 @ $4 · Disposition to issuer (D): 234,176 (derivative) · Disposition to issuer (D): 159,187 (derivative)EDGAR
2025-07-034Hopfner Robert Lorne — DirectorCode (U): 2,923,110 @ $4 · Code (U): 1,571,741 @ $4EDGAR
2025-06-274Winton Matthew — COOGrant/award (A): 14,355 @ $0.74EDGAR
2025-06-274Subramanian Sanjay — SVP, CFO & Head of BDGrant/award (A): 6,813 @ $0.74EDGAR
2025-06-274Treco Douglas A — CEO & Chairman, DirectorGrant/award (A): 2,815 @ $0.74EDGAR
2025-05-204Bolte Axel — DirectorOption exercise (M): 152,823 @ $0.98 · Option exercise (M): 4,407 @ $0.98 · Option exercise (M): 152,823 (derivative) @ $0 · Option exercise (M): 4,407 (derivative) @ $0EDGAR
2025-04-034Treco Douglas A — CEO & Chairman, DirectorOption exercise (M): 25,000 · Sale (S): 8,819 @ $0.89 · Option exercise (M): 25,000 (derivative) @ $0EDGAR
2025-04-024Winton Matthew — COOGrant/award (A): 2,490 @ $0.77EDGAR
2025-04-024Subramanian Sanjay — SVP, CFO & Head of BDGrant/award (A): 2,490 @ $0.77EDGAR
2025-03-174Subramanian Sanjay — SVP, CFOGrant/award (A): 145,000 (derivative) @ $0 · Grant/award (A): 38,500 (derivative) @ $0EDGAR
2025-03-174Winton Matthew — COOGrant/award (A): 145,000 (derivative) @ $0 · Grant/award (A): 41,500 (derivative) @ $0EDGAR
2025-03-174Treco Douglas A — CEO, DirectorGrant/award (A): 400,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0EDGAR
2024-10-074Harris Erik — DirectorGrant/award (A): 56,000 (derivative) @ $0EDGAR
2024-10-034Winton Matthew — COOGrant/award (A): 1,710 @ $4.45EDGAR
2024-10-034Treco Douglas A — CEO, DirectorGrant/award (A): 1,710 @ $4.45EDGAR
2024-06-204Sullivan Lynne Marie — DirectorGrant/award (A): 28,000 (derivative) @ $0EDGAR
2024-06-204Bhagat Sarah M — DirectorGrant/award (A): 28,000 (derivative) @ $0EDGAR
2024-06-204Edwards Martin — DirectorGrant/award (A): 28,000 (derivative) @ $0EDGAR
2024-06-204Bolte Axel — DirectorGrant/award (A): 28,000 (derivative) @ $0EDGAR
2024-06-204Hopfner Robert Lorne — DirectorGrant/award (A): 28,000 (derivative) @ $0EDGAR
2024-06-204Mathers Edward T — DirectorGrant/award (A): 28,000 (derivative) @ $0EDGAR
2024-06-204DIAZ REINALDO M — DirectorGrant/award (A): 28,000 (derivative) @ $0EDGAR
2024-04-034Winton Matthew — COOGrant/award (A): 3,188 @ $3.33EDGAR
2024-04-034Treco Douglas A — CEO, DirectorOption exercise (M): 25,000 · Sale (S): 7,523 @ $6.94 · Option exercise (M): 25,000 (derivative) @ $0EDGAR
2024-03-154Winton Matthew — COOGrant/award (A): 175,000 (derivative) @ $0EDGAR
2024-03-154Subramanian Sanjay — SVP, CFOGrant/award (A): 165,000 (derivative) @ $0EDGAR
2024-03-154Treco Douglas A — CEO, DirectorGrant/award (A): 300,000 (derivative) @ $0EDGAR
2023-10-034Subramanian Sanjay — SVP, CFOGrant/award (A): 2,319 @ $3.57EDGAR
2023-08-034Pivotal bioVenture Partners Fund I, L.P. — Director
Pivotal bioVenture Partners Fund I G.P., L.P. — Director
Pivotal bioVenture Partners Fund I U.G.P. Ltd — Director		Purchase (P): 119,048 @ $4.80 · Purchase (P): 714,285 @ $4.80EDGAR
2023-08-034Hopfner Robert Lorne — DirectorPurchase (P): 119,048 @ $4.80 · Purchase (P): 714,285 @ $4.80EDGAR
2023-06-154Sullivan Lynne Marie — DirectorGrant/award (A): 16,000 (derivative) @ $0EDGAR
2023-06-154Bhagat Sarah M — DirectorGrant/award (A): 16,000 (derivative) @ $0EDGAR
2023-06-154Edwards Martin — DirectorGrant/award (A): 16,000 (derivative) @ $0EDGAR
2023-06-154Bolte Axel — DirectorGrant/award (A): 16,000 (derivative) @ $0EDGAR
2023-06-154Hopfner Robert Lorne — DirectorGrant/award (A): 16,000 (derivative) @ $0EDGAR
2023-06-154Mathers Edward T — DirectorGrant/award (A): 16,000 (derivative) @ $0EDGAR
2023-06-154DIAZ REINALDO M — DirectorGrant/award (A): 16,000 (derivative) @ $0EDGAR
2023-05-154Hopfner Robert Lorne — DirectorPurchase (P): 219,230 @ $6.48 · Purchase (P): 228,702 @ $6.25EDGAR
2023-05-034Bolte Axel — DirectorGrant/award (A): 100,000 (derivative) @ $0EDGAR
2023-04-044Subramanian Sanjay — SVP, CFOGrant/award (A): 979 @ $2.21EDGAR
2023-04-044Winton Matthew — COOGrant/award (A): 250,000 (derivative) @ $0EDGAR
2023-04-044Treco Douglas A — CEO, DirectorGrant/award (A): 800,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0EDGAR
2023-04-044Bolte Axel — DirectorGrant/award (A): 4,806 @ $2.21EDGAR
2023-03-304Hopfner Robert Lorne — DirectorPurchase (P): 344,592 @ $4.54EDGAR
2023-03-294Hopfner Robert Lorne — DirectorPurchase (P): 51,074 @ $3.70 · Purchase (P): 156,766 @ $4.16EDGAR
2023-03-274Subramanian Sanjay — SVP, CFOGrant/award (A): 135,000 (derivative) @ $0EDGAR

Recent 8-K events — Inozyme Pharma, Inc.

FiledFormItems reportedSource
2025-07-018-K1.02 — Termination of a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits		EDGAR
2025-06-238-K8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
2025-06-028-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2025-05-168-K1.01 — Entry into a Material Definitive Agreement
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits		EDGAR
2025-05-148-K2.01 — Completion of Acquisition or Disposition of Assets
9.01 — Financial Statements and Exhibits		EDGAR
2025-03-108-K2.02 — Results of Operations and Financial Condition
?
9.01 — Financial Statements and Exhibits		EDGAR
2025-01-108-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
2024-11-058-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
2024-10-248-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
2024-10-078-K2.01 — Completion of Acquisition or Disposition of AssetsEDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=INZY returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →